# An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

> **NCT02234323** · PHASE3 · COMPLETED · sponsor: **Bioverativ, a Sanofi company** · enrollment: 108 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** rFVIIIFc

## Key facts

- **NCT ID:** NCT02234323
- **Lead sponsor:** Bioverativ, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-12
- **Primary completion:** 2019-09-23
- **Final completion:** 2019-09-23
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2022-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02234323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02234323, "An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02234323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*